The gastrointestinal absorption of bisphosphonates is in general only about 1%. To address this problem mixtures of risedronate monosodium salt with twelve varied sugar alcohols, furanoses, pyranoses and eight gluco-, manno- and galactopyranoside derivatives as counterions were designed in an effort to prepare co-crystals/new entities with improved intestinal absorption. Crystalline forms were generated by means of kinetically and/or thermodynamically controlled crystallization processes. One hundred and fifty-two prepared samples were screened by means of FT-NIR and FT-Raman spectroscopy. No co-crystal was prepared, but noteworthy results were obtained. A new solid phase of risedronate monosodium salt generated in the presence of phenyl-β-d-galactopyranoside under thermodynamically controlled crystallization conditions was found and also characterized using solid state NMR spectroscopy, X-ray powder diffraction and differential scanning calorimetry. This new polymorph was named as form P. Interactions between risedronate monosodium salt and both carbohydrates were confirmed by means of molecular dynamics simulation. In the present study the relationships between the chemical structures of the studied compounds required for crystalline form change are discussed.

Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Palackeho 1 3 61242 Brno Czech Republic

Zobrazit více v PubMed

Pharmaterials Ltd. [(accessed on 11 January 2011)]. Available online: http://www.pharmaterials.co.uk/co-crystals.html.

Tiekink E.R.T., Vittal J., editors. Frontiers in Crystal Engineering. Wiley-VCH; Wienheim, Germany: 2005.

Braga D., Grepioni F., editors. Making crystals by Design: Methods, Techniques and Applications. Wiley-VCH; Wienheim, Germany: 2006.

Ebetino F.H., Francis M.D., Rogers M.J., Russell R.G.G. Mechanisms of action of etidronate and other bisphosphonates. Rev. Contemp. Pharmacother. 1998;9:233–243.

Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991;88:2095–2105. doi: 10.1172/JCI115539. PubMed DOI PMC

Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H., Blair H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 1990;85:456–461. doi: 10.1172/JCI114459. PubMed DOI PMC

Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995;10:1478–1487. PubMed

Selander K.S., Monkkonen J., Karhukorpi E.K., Harkonen P., Hannuniemi R., Vaananen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 1996;50:1127–1138. PubMed

Ito M., Amizuka N., Nakajima T., Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone. 1999;25:447–452. doi: 10.1016/S8756-3282(99)00197-0. PubMed DOI

Reszka A.A., Halasy-Nagy J.M., Masarachia P.J., Rodan G.A. Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during Apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. 1999;274:34967–34975. PubMed

Rogers M.J., Xiong X., Brown R.J., Watts D.J., Russell R.G., Bayless A.V., Ebetino F.H. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol. Pharmacol. 1995;47:398–402. PubMed

Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–2978. doi: 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L. PubMed DOI

van Beek E.R., Lowik C.W., Ebetino F.H., Papapoulos S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone. 1998;23:437–442. doi: 10.1016/S8756-3282(98)00120-3. PubMed DOI

MedicineNet. [(accessed on 11 January 2011)]. Available online: http://www.medicinenet.com/risedronate/article.htm.

eMedTV – Health Information Brought to Life™. [(accessed on 11 January 2011)]. Available online: http://osteoporosis.emedtv.com/

Ezra A., Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Del. Rev. 2000;42:175–195. doi: 10.1016/S0169-409X(00)00061-2. PubMed DOI

Kerns E.H., Li D. Drug-like Properties: Concept, Structure Design and Methods. Elsevier; San Diego, CA, USA: 2008.

Luypaert J., Massart D.L., Vander-Heyden Y. Near-infrared spectroscopy applications in pharmaceutical analysis. Talanta. 2007;72:865–883. doi: 10.1016/j.talanta.2006.12.023. PubMed DOI

Jampilek J., Oktabec Z., Pekarek T., Havlicek J., Dohnal J., Kral V. Characterization of polymorphs and API-excipient co-crystals using vibration spectroscopy and solid-state NMR; Proceedings of the 11th International Workshop on Physical Characterization of Pharmaceutical Solids (IWPCPS® 11); Stamford, CT, USA. 14-19 June 2009.

Jampilek J., Oktabec Z., Rezacova A., Placek L., Kos J., Havelkova L., Dohnal J., Kral V. Preparation and properties of new co-crystals of ibandronate; Proceedings of the 13th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-13); 1-30 November 2009.

Jampilek J., Kos J., Oktabec Z., Mandelova Z., Pekarek T., Tkadlecova M., Havlicek J., Dohnal J., Kral V. Co-crystal screening study of risedronate and unsubstituted hexoses; proceedings of the 14th International Electronic Conference on Synthetic Organic Chemistry (ECSOC-14); 1-30 November 2010.

Oktabec Z., Kos J., Havelkova L., Mandelova Z., Pekarek T., Rezacova A., Placek L., Tkadlecova M., Havlicek J., Dohnal J., Jampilek J. Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives. Molecules. 2010;15:8973–8987. doi: 10.3390/molecules15128973. PubMed DOI PMC

Richter J., Jirman J. Crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid. Zentiva, a.s. 7,276,604. U.S. Patent. 2007 Oct 2;

Cazer F.D., Perry G.E., Billings D.M., Redman-Furey N.L. Selective crystallization of 3-pyridyl-1-hydroxy-ethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate. EP1252170 A2. Warner Chilcott Company, LLC; 2001 Feb 1;

Aronhime J., Lifshitz-Liron R., Kovalevski-Ishai E., Lidor-Hadas R. Novel polymorphs and pseudopoly-morphs of risedronate sodium. CA2480764 A1. TEVA Pharmaceutical Industries, Ltd; 2003 Oct 23;

Aronhime J., Lifshitz-Liron R., Kovalevski-Ishai E., Lidor-Hadas R. Novel polymorphs and pseudopolymorphs of risedronate sodium. WO 03/086355 A1. TEVA Pharmaceutical Industries, Ltd; 2003 Oct 23;

Redman-Furey N.L., Ficka M., Bigalow-Kern A., Cambron R.T., Lubey G., Lester C., Vaughn D. Structural and analytical characterization of three hydrates and an anhydrate form. J. Pharm. Sci. 2005;94:893–911. doi: 10.1002/jps.20308. PubMed DOI

Gossman W.L., Wilson S.R., Oldfield E. Three hydrates of the isphosphonates risedronate, consisting of one molecular and two ionic structures. Acta Cryst. C. 2003;59:m33–m36. doi: 10.1107/S0108270102021996. PubMed DOI

Bruning J., Petereit A.C., Alig E., Bolte M., Dressman J.B., Schmidt M.U. Characterization of a new solvate of risedronate. J. Pharm. Sci. 2011;100:863–873. doi: 10.1002/jps.22327. PubMed DOI

Avogadro: An Open-source Molecular Builder and Visualization Tool, Version 1.0.1. [(accessed on 28 April 2010)]. Available online: http://avogadro.openmolecules.net/

Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Montgomery J.A., Jr., Vreven T., Kudin K.N., Burant J.C., Millam J.M., Iyengar S.S., Tomasi J., Barone V., Mennucci B., Cossi M., Scalmani G., Rega N., Petersson G.A., Nakatsuji H., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Klene M., Li X., Knox J.E., Hratchian H.P., Cross J.B., Bakken V., Adamo C., Jaramillo J., Gomperts R., Stratmann R.E., Yazyev O., Austin A.J., Cammi R., Pomelli C., Ochterski J.W., Ayala P.Y., Morokuma K., Voth G.A., Salvador P., Dannenberg J.J., Zakrzewski V.G., Dapprich S., Daniels A.D., Strain M.C., Farkas O., Malick D.K., Rabuck A.D., Raghavachari K., Foresman J.B., Ortiz J.V., Cui Q., Baboul A.G., Clifford S., Cioslowski J., Stefanov B.B., Liu G., Liashenko A., Piskorz P., Komaromi I., Martin R.L., Fox D.J., Keith T., Al-Laham M.A., Peng C.Y., Nanayakkara A., Challacombe M., Gill P.M.W., Johnson B., Chen W., Wong M.W., Gonzalez C., Pople J.A. Gaussian 03, Revision C.02. Gaussian, Inc.; Wallingford, CT, USA: 2004.

Case D.A., Darden T.A., Cheatham T.E., III, Simmerling C.L., Wang J., Duke R.E., Luo R., Merz K.M., Pearlman D.A., Crowley M., Walker R.C., Zhang W., Wang B., Hayik S., Roitberg A., Seabra G., Wong K.F., Paesani F., Wu X., Brozell S., Tsui V., Gohlke H., Yang L., Tan C., Mongan J., Hornak V., Cui G., Beroza P., Mathews D.H., Schafmeister C., Ross W.S., Kollman P.A. AMBER 9. University of California; San Francisco, CA, USA: 2006.

Preparation of risedronate nanoparticles by solvent evaporation technique